logo-loader
viewFrontier IP Group PLC

Frontier IP’s Exscientia signs £200mln collaboration deal with Bayer

Exscientia will initially work on three projects focused on accelerating the discovery of small molecule drugs using its AI-powered discovery platform, Centaur Chemist

Frontier IP Group PLC - Frontier IP’s Exscientia signs £200mln collaboration deal with Bayer

Frontier IP Group PLC’s (LON:FIPP) portfolio company, Exscientia has signed a collaboration deal worth up to £203mln (€240mln) with German pharmaceutical giant Bayer focused on oncology and cardiovascular disease.

Under the terms of the deal, Exscientia will initially work on three projects focused on accelerating the discovery of small molecule drugs using its Centaur Chemist platform, which uses artificial intelligence to identify new drugs.

WATCH: Frontier IP Group 'well positioned for another positive performance'

The firm will receive upfront, research and clinical milestone payments alongside the possibility of sales royalties from any treatments developed.

“Since our pioneering Nature papers demonstrating the automated design of small-molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners", said Andrew Hopkins, Exscientia’s chief executive.

Frontier IP currently holds a 3.25% stake in Exscientia.

Quick facts: Frontier IP Group PLC

Price: 75.5 GBX

AIM:FIPP
Market: AIM
Market Cap: £41.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

on 19/6/20

2 min read